Inhibition of spring viraemia of carp virus replication in an Epithelioma papulosum cyprini cell line by RNAi

M Gotesman¹, H Soliman¹,², R Besch³ and M El-Matbouli¹

¹ Clinical Division of Fish Medicine, University of Veterinary Medicine, Vienna, Austria
² Fish Medicine and Management, Faculty of Veterinary Medicine, University of Assiut, Assiut, Egypt
³ Clinic and Policlinic for Dermatology and Allergology, Department of Dermatology, Ludwig-Maximilian University, Munich, Germany

Abstract

Spring viraemia of carp virus (SVCV) is an aetiological agent of a serious disease affecting carp farms in Europe and is a member of the Rhabdoviridae family of viruses. The genome of SVCV codes for five proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) and RNA-dependent RNA polymerase (L). RNA-mediated interference (RNAi) by small interfering RNAs (siRNAs) is a powerful tool to inhibit gene transcription and is used to study genes important for viral replication. In previous studies regarding another member of Rhabdoviridae, siRNA inhibition of the rabies virus nucleoprotein gene provided in vitro and in vivo protection against rabies. In this study, synthetic siRNA molecules were designed to target SVCV-N and SVCV-P transcripts to inhibit SVCV replication and were tested in an epithelioma papulosum cyprini (EPC) cell line. Inhibition of gene transcription was measured by real-time quantitative reverse-transcription PCR (RT-qPCR). The efficacy of using siRNA for inhibition of viral replication was analysed by RT-qPCR measurement of a reporter gene (glycoprotein) expression and by virus end-point titration. Inhibition of nucleoprotein and phosphoprotein gene expression by siRNA reduced SVCV replication. However, use of tandem siRNAs that target phosphoprotein and nucleoprotein worked best at reducing SVCV replication.

Keywords: nucleoprotein, phosphoprotein, real-time quantitative reverse-transcription PCR, Rhabdoviridae, siRNA.

Introduction

Spring viraemia of carp virus (SVCV) was initially isolated and characterized as the aetiological agent of a serious disease affecting carp farms of Central and Eastern Europe (Fijan et al. 1971; Ahne 1978). Since then, the virus has been reported in Russia (Oreshkova et al. 1999) and detected in tissue samples originating from Hungary and Czech Republic (Koutná et al. 2003). Recently, the virus has been isolated in China (Teng et al. 2007), and SVCV-associated mass mortality events were reported in the United States (Dikkeboom et al. 2004; Phelps et al. 2012). SVCV is a member of the Rhabdoviridae family of viruses; in addition to carp, other Rhabdoviruses infect multiple forms of fresh water fish and marine life (Talbi et al. 2011).

The genome of SVCV consists of a single-stranded, negative-sense RNA molecule of 11019 nucleotide bases and codes for five proteins from 3' to 5' direction (Hoffmann, Schütze & Mettenleiter 2002): nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) and RNA-dependent RNA polymerase (L). All five viral proteins L, G, P, N and M with respective masses of 238, 69, 50, 47 and 25 kDa, have been visualized by Coomassie staining, and SVCV proteins G, P and N have also been recognized by different monoclonal antibodies, which are each

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Correspondence M El-Matbouli, Clinical Division of Fish Medicine, University of Veterinary Medicine, Veterinärplatz 1, Vienna 1210, Austria (e-mail: Mansour.El-Matbouli@vetmeduni.ac.at)
specific for the respective protein (Chen et al. 2008). SVCV-G shares high protein sequence homology to other Rhabdoviridae glycoproteins (Johnson et al. 1999). The N and P proteins of SVCV are associated with the viral genome and play an important role in viral transcription and replication (Roy 1981). In the influenza virus, nucleoprotein interacts with viral polymerase during transcription and replication (Portela & Digard 2002) and binds to single-stranded RNA to stabilize and package viral template (Coloma et al. 2009). In vesicular stomatitis virus, phosphoprotein serves as a bridge between RNA template and the polymerase via the N-domain and also functions in regulating the processivity of the polymerase using a 26-amino acid stimulatory domain (Rahmeh et al. 2012).

RNA-mediated interference (RNAi) by double-stranded RNA (dsRNA) was originally demonstrated in Caenorhabditis elegans in studying the twitching phenotype caused by the disruption of a non-essential myofilament protein termed 'unc-22' by Fire et al. (1998). Since then, the mechanism and machinery for small non-coding RNA to function in RNAi has been worked out in great detail for a myriad of organisms in terms of gene silencing of either endogenous- or exogenous-derived transcripts by the respective microRNA (miRNA) pathway (Stefani & Slack 2008) and small interfering (siRNA) pathway (Sifuentes-Romero, Milton & García-Gasca 2011), and for DNA elimination by the scan RNA (scnRNA) pathway (Mochizuki 2010). During gene silencing of exogenous transcripts, the RNA-induced silencing complex (RISC) converts long dsRNA transcripts into short double-stranded RNA oligonucleotides (21–25nt), which later guide the RNAi machinery to degrade targeted genes via antisense recognition (Kim et al. 2006). The cleavage of long dsRNAs into short oligonucleotides is processed by an RNase III enzyme termed Dicer, and thereafter, in some organisms, the oligo is incorporated into either the miRNA or siRNA pathway, depending on which Dicer homolog processed the oligo (Lee et al. 2004). Argonaute, which was initially indentified in Arabidopsis thaliana, along with the piwi subfamily are the main protein components of RISC used in many organisms to determine the post-transcriptional gene-silencing pathway (Mallory & Vaucheret 2010). Currently, RNAi-based technology has been refined to be used to inhibit a gene of interest by synthetically generated double-stranded RNA (dsRNA) oligonucleotides that have antisense recognition to targeted genes. Transfection of these synthetic small interfering RNAs (siRNAs) into cells leads to silencing of the targeted transcript. This technique is used in a myriad of applications that include gene function analysis and therapeutics (Gavrilo & Saltzman 2012) and has been suggested to be useful in fish medicine to combat various types of diseases that are caused by viral and parasitic agents (Lima, Harris & Cook 2013).

Previous attempts at protecting carp from SVCV using a DNA vaccine that drives the expression of the SVCV-G protein provided varying degree of protection from SVCV-induced mortality (Kanellos et al. 2006; Emmenegger & Kurath 2008). However, DNA vaccines must be administered prior to infection to allow for a robust immune response to develop and cannot be used to treat infected fish. Conversely, RNAi-based strategy may yield higher in vivo protection to SVCV than DNA vaccines and may lead to a therapy strategy to save SVCV-infected fish. In studies that use siRNA to target the mammalian-specific viruses of the Rhabdoviridae family (RABV), silencing the nucleoprotein resulted in vitro and in vivo protection from infection with the rabies virus (Gupta et al. 2012; Yang et al. 2012). This current study tests the feasibility of using synthetic dsRNA oligonucleotides (21 nt) that target SVCV-N and SVCV-P genes to inhibit in vitro SVCV replication utilizing in an epithelioma papulosum cyprini (EPC) cell line. The findings from this study may ultimately lead to a novel method to protect fish from SVCV and a strategy to treat SVCV-infected fish. The siRNA molecules were designed to target SVCV-N and SVCV-P transcripts. The knock-down (KD) efficiency of the siRNA molecules was measured by real-time quantitative reverse-transcription PCR (RT-qPCR). The inhibition of viral replication was also measured by quantifying the expression of a reporter gene (glycoprotein) by RT-qPCR as performed in similar studies (Ruiz et al. 2009) and by virus endpoint titration in cell culture (Reed & Muench 1938).

Materials and methods

Cell culture

The epithelioma papulosum cyprini (EPC-173) was propagated in ZB5 medium: MEM Earle’s salts
480 mL L\(^{-1}\) (Invitrogen), MEM, Hank's salt 480 mL L\(^{-1}\) (Invitrogen), Gibco non-essential amino acids 10 mL L\(^{-1}\) (Invitrogen), Na-pyruvate 120 mg L\(^{-1}\) with 10% per volume foetal bovine serum (FBS) and antibiotic/antimycotic mix (Sigma-Aldrich). For cell culture passaging, EPC cells (after reaching a minimum of 70% confluence) were split in an 1:3 ratio by trypsinization and seeded in fresh ~5 mL medium in 25-cm\(^2\) cell culture flasks (Sigma-Aldrich), at initial concentrations of approximately 2.4 \(\times\) 10\(^5\) cells mL\(^{-1}\) at 20 °C. For experimental conditions with siRNA, EPC cells (after reaching a minimum of 70% confluence) were split in a 1:2 ratio and seeded on 24-well cell culture plates (Sigma-Aldrich), at initial concentrations of approximately 3.6 \(\times\) 10\(^5\) mL\(^{-1}\) cells in 1 mL of media per well, at 20 °C.

### Tissue extraction

Tissues (kidney and spleen) from a carp confirmed by PCR and sequencing to be infected with SVCV were homogenized in minimum essential medium. An aliquot of the homogenate was used for propagation of SVCV in the aforementioned EPC cell line. After propagation, total RNA extracted from the supernatant was later used as a positive (POS) control for SVCV replication.

### Viral propagation

Two days post-seeding, 25-cm\(^2\) cell culture flasks were emptied of media and covered with 0.5 mL of previously propagated SVCV aliquots. After 1 h of incubation at 20 °C, the flask culture was replenished with an additional 5 mL of ZB5 medium and further incubated at 20 °C for an additional 2 days. The resulting supernatant was collected into aliquots and stored at −80 °C.

### Viral titration

Fresh EPC cells were seeded on Cellstar 96-well plate (Greiner Bio-One), at initial concentrations of approximately 2.4 \(\times\) 10\(^5\) cells mL\(^{-1}\) in 225 \(\mu\)L of medium, per well at 20 °C. Two days post-seeding, 25-\(\mu\)L aliquots of 10\(^x\) serial dilutions of SVCV supernatant (as previously described) were added to each well. Cytopathic effect (CPE) was observed 2 days after seeding, but wells were scored 4 days after seeding. Reed & Muench’s (1938) method was used to calculate Tissue Culture Infective Dose 50% (TCID\(_{50}\)) mL\(^{-1}\).

### siRNA design

Small interfering double-stranded RNAs to target SVCV nucleoprotein and phosphoprotein genes, GenBank access number NC_002803, respective Gene ID’s: 921324 and 921323, were designed using Block-iT RNAi Designer (Invitrogen) and were synthesized by Ambion (Invitrogen) to carry dTdT 3’ overhangs. Two different siRNAs were developed to target regions in the nucleoprotein gene: the first one termed ‘N’ (GGGAUAGCU UCUGCACACATT, antisense strand 5’-UUGU GUCCGAAGCUUUCCTT) targets (GGGATA GCTTCGAGACACA), and another one termed ‘N1’ (sense strand: GCUGAUGGAUUUCGUU UATT, antisense strand 5’-UAUCAGGGUUUC AUCAGCTT) targets (GCTGATGGAATCCCTGATA). Similarly, two different siRNAs were developed to target regions in the phosphoprotein gene: the first one termed ‘P’ (sense strand: GGAAUCAGAUUUCGGGAGAUTT, antisense strand 5’-AUCUCGGGAUUCUUCCTT) targets (GGGATA GCTTCGAGACACA), and another one termed ‘P1’ (sense strand: CCUGAU UACCUCAGAGAAATT, antisense strand 5’-UU UCUCUGAGGUAAUCAGTT) targets (CCTG ATTACCTCAGAAAA). Two siRNAs targeting non-SVCV regions, but regions of a different fish virus (Cyprinid herpesvirus-3), were used as controls. One siRNA is termed ‘DP’ (CCUCUA CAACGUGCACAUUTT, AAAGUGCACGUU GUAGAGTT), and the other siRNA is termed ‘TK’ (UCGACGAGGGACGUUCUTT, AAG AACUGUCCCUCUGGTT). Sense and antisense strands were resuspended in DEPC-treated water to obtain 20 \(\mu\)M (0.266 \(\mu\)g \(\mu\)L\(^{-1}\)) solutions, heated at 90 °C for 1 min for denaturation and incubated at 37 °C for 60 min for annealing. They were next allowed to cool to room temperature and were aliquoted for use.

### siRNA application

One day after seeding EPC cells into fresh 24-well plates, siRNA was transfected according to the manufacturer’s instructions in the 24-well plates. Briefly, siRNA was resuspended in separate
100 µL opti-men® I reduced-serum medium aliquots (Invitrogen) and incubated with 1 µL Lipofectamine® LTX reagent (Invitrogen) at room temperature for 30 min, and the appropriate siRNA solution was applied into individual wells. The plates were returned to incubate at 20 °C for an additional 24 h.

Virus application

In the first trial, following the siRNA application (the third day after seeding), medium from a plate was replaced with fresh medium supplemented with SVCV at 105.85 TCID50 mL−1 returned to incubation at 20 °C. On the next day (the fourth day after seeding), the medium was also replaced with fresh medium and returned to incubation at 20 °C. The following day, media were collected and aliquoted for RNA extraction and viral titre analysis. The second trial was performed in duplicates; following the siRNA application (on the third day of the trial), medium was supplemented with SVCV to form a final concentration of 104.85 TCID50 mL−1 and returned to incubate at 20 °C. Two days later, the fifth day after seeding (as performed in our initial trial), medium was collected and aliquoted for RNA extraction and viral titre analysis.

RT-qPCR analysis

Total viral RNA was extracted from 200 µL medium fractions using the QIAamp viral RNA mini kit (Qiagen). RNA expression for released viral particles was measured in duplicates using the CFX real-time system attached to a C100 Touch thermal cycler (Bio-Rad). Primer sets coding for a region in SVCV-N gene, forward primer (FP)-AACAGCGCTAAGGCGTAAGCCATGAC, and reverse primer (RP)-FAM-ATGA AGARGAGTAAACKGCCTGCAAA CAGA-BHQ1) were used for RT-qPCR with SYBR Green I. Analysis of both SVCV nucleoprotein and phosphoprotein genes showed that 1 µL (0.266 µg µL−1) treatment of siRNA per 1-mL wells for a final concentration of 20 nM of siRNA per well targeting either SVCV-N or SVCV-P transcripts inhibited expression of those respective transcripts nominally as compared to untreated or control siRNA (Fig. 2a–b). Addition of 2 µL (0.532 µg µL−1) of either siRNAs for a 40 nM final concentration or the simultaneous addition of 1 or 2 µL of each siRNAs for respective final concentrations of 40 or 80 nM of combined siRNA per well was more effective at decreasing the expression of SVCV-N and SVCV-P transcripts. The reduction in mRNA transcript levels for the nucleoprotein gene by doubling the amount of siRNA used resulted in decreases of 25% and 55% when siRNAs against either N or P were used, respectively. And the reduction in mRNA transcript levels for the phosphoprotein gene by doubling the amount of siRNA used resulted in decreases of 24% and 38% when siRNAs against either N or P were used, respectively. However, targeting both genes by treatment with 2 µL of each siRNA produced only a nominal difference in transcription of
either N or P genes, as compared to treatment with only 1 µL of each siRNA. The melt curves of these primer sets show them to be specific for their intended targets (Fig. 2c–d) and showing a lower T_m only in the no template control (NTC) possibly indicating the formation of primer dimers in the NTC (Bustin & Nolan 2004). Primer dimers in the NTC are a common phenomenon of qPCR with SYBR Green I and are difficult to eliminate (Ponchel et al. 2003). A standard curve for each primer set was tested for the detection of SVC virus and showed the primers to be efficient for the detection of the virus (Fig. 2e–f).

According to TaqMan hydrolysis RT-qPCR, levels of SVCV-glycoprotein gene expression were similar in RNA extractions from virus propagation in either cell culture (no siRNA) or tissue extraction (POS) control, and that siRNA targeting SVCV-P was more effective than targeting SVCV-N at reducing mRNA transcripts for SVCV-G (Fig. 3a). Also, the addition of 2 µL of siRNA targeting SVCV-P or the simultaneous addition of 1 or 2 µL of each siRNAs significantly decreased the TICD_50 mL^-1 as much as 13- to 18-fold as compared to untreated sample or mistargeted siRNA, respectively.

**Second trial**

To determine whether siRNA treatment was more effective during an infection beginning with a lower viral load, we repeated our first trial with an initial viral load concentration of 10^{4.85} TCID_50 mL^-1. A significant difference of reduction for glycoprotein transcription was observed in all treatments with siRNA compared with the control groups, as measured by RT-qPCR (Fig. 4). As in our previous trial, the use of 2 µL of either siRNAs or addition of 1 or 2 µL of each siRNAs was most effective at reducing SVCV replication (Table 1).

**Discussion**

Spring viraemia of carp virus is a major disease affecting the European carp industry (Ahne et al. 2002) and is most active during the spring weather, when the temperature is between 10 and 20 °C (Ahne 1986). In natural infection by SVCV, entry and early replication is via the gills, followed by dispersal via the blood stream to the kidney, liver, spleen and other major organs (Ahne 1978). Detection methods for SVCV include cell culture propagation (Ahne 1978), enzyme-linked immunosorbent assay (Rodák et al. 1993), competitive immunoassay (Dixon, Hattenberger-Baudouy & Way 1994) and newer methods...
include RT-qPCR (Yue et al. 2008) and visual-based methods that use gold nanoparticles (Saleh et al. 2012). SVCV replicates in the cytosol and both nucleoprotein and phosphoprotein are phosphorylated (Sokol & Koprowski 1975). In addition to having sites for phosphorylation, both aforementioned proteins likely interact with the RNA-dependent polymerase as described in other RNA viruses (Coloma et al. 2009; Rahmeh et al. 2012). Although several antiviral genes, as well as the interferon pathway, are upregulated during SVCV infection (Adamek et al. 2012), the mortality rate for young carp can reach up to 70% during spring time outbreaks (Ahne et al. 2002). The defensive capabilities of cells against viral infection can be enhanced using different forms of RNA that include RNAi (Porntrakulpipat et al. 2010; Hwang et al. 2012). The RNAi machinery can be induced by synthetic double-stranded RNA oligonucleotides (21–22nt), termed ‘siRNAs’ (Elbashir, Lendeckel & Tuschl 2001b). The efficiency for knock-down by siRNA duplexes ranges from 2- to

**Figure 2** Quantification of siRNA knock-down. The efficiency of siRNA knock-down of spring viraemia of carp virus (SVCV) genes was evaluated by RT-qPCR using SYBR Green I, as described in the methods. For figures a–b, the y-axis refers to relative gene copy number as compared to the sample with the highest copy number, the x-axis refers to the volume and type of siRNA administered. N (nucleoprotein), P (phosphoprotein), DP and TK are control sequences as described in the methods. The volume 1 µL is equivalent to 20 µM (0.266 µg µL⁻¹) of siRNA duplexes, and 2 µL is 40 µM (0.532 µg µL⁻¹). (a) RT-qPCR measuring nucleoprotein transcripts (b) RT-qPCR measuring phosphoprotein transcripts. For figures c–d, meltcurves for RT-qPCR measuring (c) nucleoprotein transcripts, intended product at −83 °C, primer dimers for no template control (NTC) at −73 °C (d) phosphoprotein transcripts, intended product at −79 °C, primer dimers for no template control (NTC) at −74 °C. For figures e–f, standard curves for the primers were made, (e) nucleoprotein and (f) phosphoprotein.
25-fold and is dependent on various factors, such as gene of target, region targeted and cell line used (Elbashir et al. 2001a). The siRNA knock-down (KD) of the nucleoprotein from another fish rhabdovirus, termed ‘viral hemorrhagic septicemia virus’ (VHSV), greatly reduced clearance capacity of the virus on EPC cells (Ruiz et al. 2009). RNAi-mediated knock-down of other VHSV genes in EPC has also been shown to inhibit viral infection (Kim & Kim 2011; Kim et al. 2012). For Rabies virus, targeting nucleoprotein transcripts by siRNA showed higher inhibition than targeting the polymerase (Gupta et al. 2012). However, we are unaware of a study that uses RNAi to investigate the inhibition of SVCV. In this study, we designed siRNAs that target either SVCV-N or SVCV-P genes to inhibit in vitro SVCV replication in EPC. In addition, novel primers were developed to quantify SVCV-N or SVCV-P mRNA transcription.

The efficiency of knocking down either SVCV-N or SVCV-P transcripts in reducing viral activity was evaluated by two different methods: one that uses TaqMan hydrolysis RT-qPCR to measure the reduction of a reporter gene (glycoprotein) and another one that measures the reductivity of viral activity in cell culture (Reed & Muench 1938). Both methods showed that siRNA knock-down of either SVCV-N or SVCV-P transcripts reduced viral activity. According to the TaqMan hydrolysis RT-qPCR results, siRNA targeting of either phosphoprotein or nucleoprotein genes alone inhibited SVCV-G transcription. However, viral titration in cell culture showed a strong correlation for inhibition of virus replication in response to the amount of siRNA treatment, and the use of tandem siRNAs that target both SVCV-N and SVCV-P genes was the most effective at inhibition of SVCV replication. As opposed to dsRNA that are 30nt or longer that can activate the interferon
response pathway, dsRNA that are between 21 and 25nt have been shown to target specific silencing mechanisms (Caplen et al. 2001). To confirm that inhibition of gene transcription and viral replication was specific to the chosen siRNAs and not a general response by the interferon or other host defence pathway, siRNAs targeting another virus were chosen as controls. The control siRNAs did not show any effects on SVCV, which suggests that the inhibition of gene transcription and viral replication was a specific response induced by the RNAi machinery.

Previously, in vivo application of RNAi has been shown to combat white spot syndrome virus (WSSV), an aquatic viral disease of shrimp (Sarathi et al. 2010). The results of this study should also be tested in an in vivo model to determine how well SVCV replication can be inhibited by

Table 1  Inhibition of viral replication by siRNA

| Group | Treatment | Relative Quantity SVCV-G | \(10^6\) TCID_{50} mL\(^{-1}\) |
|-------|-----------|--------------------------|-------------------------------|
| N     | 1 \(\mu\)L N  | 0.10026                  | 5.3750                        |
|       | 2 \(\mu\)L N  | 0.05329                  | 3.3155                        |
|       | 1 \(\mu\)L N1 | 0.10428                  | 4.1850                        |
|       | 2 \(\mu\)L N1 | 0.15969                  | 1.9800                        |
|       | 1 \(\mu\)L N + 1 \(\mu\)L N1 | 0.15658 | 7.1450 |
|       | 2 \(\mu\)L N + 2 \(\mu\)L N1 | 0.11062 | 4.1850 |
| P     | 1 \(\mu\)L P  | 0.10975                  | 7.1450                        |
|       | 2 \(\mu\)L P  | 0.09270                  | 7.7050                        |
|       | 1 \(\mu\)L P1 | 0.10115                  | 5.9200                        |
|       | 2 \(\mu\)L P1 | 0.11570                  | 3.8050                        |
|       | 1 \(\mu\)L P + 1 \(\mu\)L P1 | 0.19434 | 9.2850 |
|       | 2 \(\mu\)L P + 2 \(\mu\)L P1 | 0.12242 | 6.3350 |
| N + P | 1 \(\mu\)L N + 1 \(\mu\)L P | 0.04837 | 1.9800 |
|       | 2 \(\mu\)L N + 2 \(\mu\)L P | 0.07659 | 1.9800 |
|       | 1 \(\mu\)L N1 + 1 \(\mu\)L P1 | 0.07530 | 6.9300 |
|       | 2 \(\mu\)L N1 + 2 \(\mu\)L P1 | 0.07528 | 3.5900 |
| Control | 2 \(\mu\)L DP + 2 \(\mu\)L TK | 0.95522 | 17.7050 |
|       | no siRNA    | 1.00000                  | 19.7000                        |

The inhibition of viral replication by specific siRNAs was measured by RT-qPCR of a viral reporter gene (glycoprotein) and by virus endpoint titration. The treatments were grouped in terms of siRNA targeting nucleoprotein (N), phosphoprotein (P), a combination of the two N + P or controls. The relative quantity is given in comparison with treatment with no siRNA in the 3rd column as measured by RT-qPCR. Similarly, the 4th column shows the average of two TCID_{50} mL\(^{-1}\) trials.

Figure 4 Inhibition of viral replication in the second trial. For figures a-d, TaqMan hydrolysis RT-qPCR was used to measure the inhibition of viral replication. The y-axis refers to relative gene copy number of glycoprotein as compared to the sample with no siRNA treatment, the x-axis refers to the volume and type of siRNA administered, N and N1 refer to siRNAs targeting nucleoprotein, P and P1 refer to (phosphoprotein), and DP and TK are control sequences as described in the methods. The volume 1 \(\mu\)L is equivalent to 20 \(\mu\)M (0.266 \(\mu\)g \(\mu\)L\(^{-1}\)) of siRNA duplexes and 2 \(\mu\)L is 40 \(\mu\)M (0.532 \(\mu\)g \(\mu\)L\(^{-1}\)).
RNA-mediated interference. Earlier studies have outlined some of the difficulties of transferring positive results for siRNA studies from in vitro to in vivo trials (Schyth 2008), such as the temporary effect of siRNAs and the activation of the interferon response pathway (Schyth, Lorenzen & Pedersen 2007). The chemical modifications of siRNAs (Schyth et al. 2012) or the use of longer dsRNA (27/25 mer) that is a cellular substrate target of dicer (Bohle, Lorenzen & Schyth 2011) provide for alternative methods to study the in vivo effects of siRNA knock-down. Although current EPC lineages are contaminated with cells from another cyprinid, fathead minnow Pimephales promelas (Winton et al. 2010), EPC remains a current subject for the study of RNAi in fish cells (Kim & Kim 2011; Kim et al. 2012) and for the host dynamics of SVCV infection (Liu et al. 2013).

Conclusion

According to our results, knock-down by synthetic siRNA of phosphoprotein or nucleoprotein reduces viral particle release from an epithelioïd papulosum cyprini cell line infected with SVCV. The use of siRNAs in tandem, which target phosphoprotein and nucleoprotein, works best in reducing in vitro viral replication. In addition, two sets of primers were developed to measure SVCV-N or SVCV-P mRNA transcription.

Acknowledgements

The EPC cell line and SVCV-inoculum were kindly provided by Dr Bergmann and Dr Fichtner; Friedrich Loeffler Institute (FLI), the national research centre for animal health in Greifswald, Germany. We would also like to thank Dr Andrea Dressler for technical assistance, and Julia Kartlun and Dr Oskar Schachner for laboratory assistance, and Dr Alexander Tichy for help with statistical analysis. Funding for this project was supported by the Austrian Science Fund (FWF) Grant No. P 23550-B13.

References

Adamek M., Rakus K.L., Chyb J., Brogden G., Huebner A., Irnazarow I. & Steinhagen D. (2012) Interferon type I responses to virus infections in carp cells: in vivo studies on Cyprinid herpesvirus 3 and Rhabdovirus carpio infections. Fish & Shellfish Immunology 33, 482–493.

Ahne W. (1978) Uptake and multiplication of spring viremia of carp virus in carp, Cyprinus carpio L. Journal of Fish Diseases 1, 265–268.

Ahne W. (1986) The influence of environmental temperature and infection route on the immune response of carp (Cyprinus carpio) to spring viremia of carp virus (SVCV). Veterinary Immunology & Immunopathology 12, 383–386.

Ahne W., Bjorklund H.V., Essbauer S., Fijan N., Kurath G. & Winton J.R. (2002) Spring viremia of carp (SVC). Diseases of Aquatic Organisms 52, 261–272.

Bohle H., Lorenzen N. & Schyth B.D. (2011) Species specific inhibition of viral replication using dicer substrate siRNAs (DsiRNAs) targeting the viral nucleoprotein of the fish pathogenic rhabdovirus viral hemorrhagic septicemia virus (VHSV). Antiviral Research 90, 187–194.

Bustin S.A. & Nolan T. (2004) Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. Journal of Biomolecular Techniques 15, 155–166.

Caplen N.J., Parrish S., Imani F., Fire A. & Morgan R.A. (2001) Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proceedings of the National Academy of Sciences of the USA 98, 9742–9747.

Chen Z.Y., Liu H., Li Z.Q. & Zhang Q.Y. (2008) Development and characterization of monoclonal antibodies to spring viraemia of carp virus. Veterinary Immunology & Immunopathology 123, 266–276.

Coloma R., Valpuesta J.M., Arranz R., Carrascosa J.L., Ortín J. & Martín-Benito J. (2009) The structure of a biologically active influenza virus ribonucleoprotein complex. PLoS Pathology 5, e1000491.

Dikkeboom A.L., Radi C., Toohey-Kurth K., Marcquenski S., Engel M., Goodwin A.E., Way K., Stone D.M. & Longshaw C. (2004) First report of spring viremia of carp virus (SVCV) in wild common carp in North America. Journal of Aquatic Animal Health 16, 169–178.

Dixon P.F., Hattenberger-Baudouy A.M. & Way K. (1994) Detection of carp antibodies to spring viremia of carp virus by a competitive immunoassay. Diseases of Aquatic Organisms 19, 181–186.

Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K. & Tuschl T. (2001a) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498.

Elbashir S.M., Lendeckel W. & Tuschl T. (2001b) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes & Development 15, 188–200.

Emmenegger E.J. & Kurath G. (2008) DNA vaccine protects ornamental koi (Cyprinus carpio koi) against North American spring viremia of carp virus. Vaccine 26, 6415–6421.
Fijan N., Petrinec Z., Sulimanovic D. & Zwilling L.O. (1971) Isolation of the viral causative agent from the acute form of infectious dropsy of carp. *Veterinarni Arhiv* **41**, 125–138.

Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E. & Mello C.C. (1998) Potent and specific interference by double-stranded RNA in Caenorhabditis elegans. *Nature* **391**, 806–811.

Gavrilov K. & Saltzman M. (2012) Therapeutic siRNA: principles, challenges, and strategies. *The Yale Journal of Biology and Medicine* **85**, 187–200.

Gupta P.K., Sonwane A.A., Singh N.K., Meshram C.D., Daiiya S.S., Pawar S.S., Gupta S.P., Chatuvedi V.K. & Saini M. (2012) Intracellular delivery of small interfering RNAs (siRNAs) using adenoviral vector protects mice against lethal peripheral rhabdies challenge. *Virus Research* **163**, 11–18.

Hoffmann B., Schütte H. & Mettenleiter T.C. (2002) Determination of the complete genomic sequence and analysis of the gene products of the virus of Spring Viremia of Carp, a fish rhabdovirus. *Journal of Virology* **84**, 89–100.

Hwang S.D., Midorikawa N., Punnarak P., Kikuchi Y., Kondo T., Hiroki H. & Aoki T. (2012) Inhibition of hitame rhabdovirus growth by RNA aptamers. *Journal of Fish Diseases* **35**, 927–934.

Johnson M.C., Maxwell J.M., Loh P.C. & Leong J.A. (1999) Molecular characterization of the glycoproteins from two warm water rhabdoviruses: snakehead rhabdovirus (SHRV) and rhabdovirus of penaeid shrimp (RPS): spring viremia of carp virus (SVCV). *Virology* **64**, 95–106.

Kanellos T., Sylvester L.D., D’Mello F., Howard C.R., Mackie A., Dixon P.F., Chang K.C., Ramstad A., Midtlyng P.J. & Russell P.H. (2006) DNA vaccination can protect Cyprinus carpio against spring viraemia of carp virus. *Vaccine* **24**, 4927–4933.

Kim M.S. & Kim K.H. (2011) Inhibition of viral hemorrhagic septicemia virus replication using a short hairpin RNA targeting the G gene. *Archives of Virology* **156**, 457–464.

Kim K., Lee Y.S., Harris D., Nakahara K. & Cattew R.W. (2006) The RNAi pathway initiated by Dicer-2 in Drosophila. *Cold Spring Harbor Symposium on Quantitative Biology* **71**, 39–44.

Kim M.S., Lee B.Y., Cho M.Y., Kim J.W., Jeong H.D. & Kim K.H. (2012) Fugu double U6 promoter-driven long double-stranded RNA inhibits proliferation of viral hemorrhagic septicemia virus (VHSV) in fish cell lines. *Archives of Virology* **157**, 1029–1038.

Koutná M., Veselý T., Psíhalová I. & Hůlová J. (2003) Identification of spring viremia of carp virus (SVCV) by combined RT-PCR and nested PCR. *Diseases of Aquatic Organisms* **55**, 229–235.

Lee Y.S., Nakahara K., Pham J.W., Kim K., He Z., Sontheimer E.J. & Cattew R.W. (2004) Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. *Cell* **117**, 69–81.

Lima P.C., Harris J.O. & Cook M. (2013) Exploring RNAi as a therapeutic strategy for controlling disease in aquaculture. *Fish & Shellfish Immunology* **34**, 729–743.

Mallory A. & Vaucheret H. (2010) Form, function, and regulation of ARGOAUTE proteins. *The Plant Cell Online* **22**, 3879–3889.

Mochizuki K. (2010) DNA rearrangements directed by non-coding RNAs in ciliates. *Wiley Interdisciplinary Reviews: RNA* **1**, 376–387.

Oreshkova S.F., Shchelkunov I.S., Tikanova N.V., Shchelkunova T.I., Puzyet A.T. & Ilyichev A.A. (1999) Detection of spring viremia of carp virus isolates by hybridization with non-radioactive probes and amplification by polymerase chain reaction. *Virus Research* **63**, 3–10.

Pelps N.B., Armien A.G., Mor S.K., Goyal S.M., Warg J.V., Bhagya R. & Monahan T. (2012) Spring viremia of carp virus in Minnehaha Creek, Minnesota. *Journal of Aquatic Animal Health* **24**, 232–237.

Ponchet F., Teoment C., Bransfield K., Leong F.T., Douglas S.H., Field S.L., Bell S.M., Comberet V., Puiseux A., Mighell A.J., Robinson P.A., Inglehearn C.F., Isaacs J.D. & Markham A.F. (2003) Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. *BMBC Biotechnology* **3**, 18.

Porntrakulpipat S., Supankong S., Chatchawanchonteera A. & Pakdee P. (2010) RNA interference targeting nucleocapsid protein (C) inhibits classical swine fever virus replication in SK-6 cells. *Veterinary Microbiology* **142**, 41–44.

Portela A. & Digard P. (2002) The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. *Journal of General Virology* **83**, 723–734.

Rahmeh A.A., Morin B., Schenk A.D., Liang B., Heinrich B.S., Bruisic V., Walt T. & Whelan S.P. (2012) Critical phosphoprotein elements that regulate polymerase architecture and function in vesicular stomatitis virus. *Proceedings of the National Academy of Sciences of the USA* **109**, 14628–14633.

Reed L.J. & Muench H. (1938) A simple method of estimating fifty percent endpoints. *American Journal of Hygiene* **27**, 493–497.

Rodák L., Pospšíl Z., Tománek J., Veselý T., Obr T. & Valiček L. (1993) Enzyme-linked immunosorbent assay (ELISA) for the detection of spring viremia of carp virus (SVCV) in tissue homogenates of the carp, Cyprinus carpio L. *Journal of Fish Diseases* **16**, 101–111.

Roy P. (1981) Phosphoproteins of spring viremia of carp virus. *Virology* **112**, 274–281.

Ruíz S., Schyth B.D., Encinas P., Tafalla C., Estepa A., Lorenzen N. & Coll J.M. (2009) New tools to study RNA interference to fish viruses: fish cell lines permanently expressing siRNAs targeting the viral polymerase of viral hemorrhagic septicemia virus. *Antiviral Research* **82**, 148–156.

Saleh M., Soliman H., Schachner O. & El-Marbouli M. (2012) Direct detection of unamplified spring viremia of carp virus RNA using unmodified gold nanoparticles. *Diseases of Aquatic Organisms* **100**, 3–10.
Sarathi M., Simon M.C., Venkatesan C., Thomas J., Ravi M., Madan N., Thiyagarajan S. & Sahul Hameed A.S. (2010) Efficacy of bacterially expressed dsRNA specific to different structural genes of white spot syndrome virus (WSSV) in protection of shrimp from WSSV infection. *Journal of Fish Diseases* 33, 603–607.

Schyth B.D. (2008) RNAi-mediated gene silencing in fishes? *Journal of Fish Biology* 72, 1890–1906.

Schyth B.D., Lorenzen N. & Pedersen F.S. (2007) A high throughput in vivo model for testing delivery and antiviral effects of siRNAs in vertebrates. *Molecular Therapy* 15, 1366–1372.

Schyth B.D., Bramsen J.B., Pakula M.M., Larashati S., Kjems J., Wengel J. & Lorenzen N. (2012) In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important. *Nucleic Acids Research* 40, 4653–4665.

Sifuentes-Romero I., Milton S.L. & García-Gasca A. (2011) Post-transcriptional gene silencing by RNA interference in non-mammalian vertebrate systems: where do we stand? *Mutation Research* 728, 158–171.

Sokol F. & Koprowski H. (1975) Structure-function relationships and mode of replication of animal rhabdoviruses. *Proceedings of the National Academy of Sciences of the USA* 72, 933–936.

Stefani G. & Slack F.J. (2008) Small non-coding RNAs in animal development. *Nature Reviews Molecular Cell Biology* 9, 219–230.

Talbi C., Cabon J., Baud M., Bourjaily M., de Boissiéon C., Castric J. & Bigarré L. (2011) Genetic diversity of perch rhabdoviruses isolates based on the nucleoprotein and glycoprotein genes. *Archives of Virology* 156, 2133–2144.

Teng Y., Liu H., Lv J.Q., Fan W.H., Zhang Q.Y. & Qin Q.W. (2007) Characterization of complete genome sequence of the spring viremia of carp virus isolated from common carp (Cyprinus carpio) in China. *Archives of Virology* 152, 1457–1465.

Winton J., Batts W., deKinkelin P., LeBerre M., Bremont M. & Fijan N. (2010) Current lineages of the epithelioma papulosum cyprini (EPC) cell line are contaminated with fathead minnow, Pimephales promelas, cells. *Journal of Fish Diseases* 33, 701–704.

Yang Y.J., Zhao P.S., Zhang T., Wang H.L., Liang H.R., Zhao L.L., Wu H.X., Wang T.C., Yang S.T. & Xia X.Z. (2012) Small interfering RNAs targeting the rabies virus nucleoprotein gene. *Virus Research* 169, 169–174.

Yue Z., Teng Y., Liang C., Xie X., Xu B., Zhu L., He J., Liu Z., Jiang Y., Liu H. & Qin Q. (2008) Development of a sensitive and quantitative assay for spring viremia of carp virus based on real-time RT-PCR. *Journal of Virological Methods* 152, 43–48.